Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.89 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.89 |
| ▸ | GPR84 | Q9NQS5 | 9/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24191085 | 0.90 | SCN9A (0.78) | SCN9ASCN5AGPR84SMN1; SMN2KDM4E | |
| SCHEMBL26039927 | 0.80 | CYP1A2 (0.75) | GPR84SMN1; SMN2 | |
| SCHEMBL15575015 | 0.77 | SCN9A (0.59) | SCN9ASCN5AKDM4E | |
| SCHEMBL27138808 | 0.76 | GPR84 (1.00) | SCN9ASCN5AGPR84SMN1; SMN2 | |
| SCHEMBL5552693 | 0.74 | SCN9A (0.55) | SCN9ASCN5A | |
| SCHEMBL24191327 | 0.73 | SCN9A (0.56) | SCN9ASCN5AKDM4E | |
| SCHEMBL17130742 | 0.71 | SMN1; SMN2 (0.70) | SMN1; SMN2KDM4E | |
| SCHEMBL28318739 | 0.71 | GPR84 (0.80) | GPR84SMN1; SMN2 | |
| SCHEMBL5094216 | 0.71 | GPR84 (0.88) | SCN9ASCN5AGPR84SMN1; SMN2 | |
| SCHEMBL3945346 | 0.71 | RAB9A (0.49) | SCN9ASCN5ASMN1; SMN2KDM4EABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303561-A1 | PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION | INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4180429-A1 | PYRIMIDINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION | Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2023-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303561-A1 | PYRIMIDINONE DERIVATIVE, PREPARATION METHOD THEREOF AND USE THEREOF IN RESISTING MYCOBACTERIUM TUBERCULOSIS INFECTION | DHPS, DHFR, QDPR | SCN9A 4613/4885SCN5A 4507/4885GPR84 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.